Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

NCT02065687 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT02065687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02065687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 17, 2014
Completion date
September 13, 2023
Enrollment
469 (actual)
Sites
431

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, recurrent uterine corpus carcinoma, stage iii uterine corpus cancer ajcc v7, stage iiia uterine corpus cancer ajcc v7, stage iiib uterine corpus cancer ajcc v7, stage iiic uterine corpus cancer ajcc v7, stage iv uterine corpus cancer ajcc v7, stage iva uterine corpus cancer ajcc v7, stage ivb uterine corpus cancer ajcc v7